Organon & Co. (OGN)
13.90
0.00 (0.00%)
USD |
NYSE |
Nov 20, 10:47
Organon Cash from Investing (Quarterly) : -44.00M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -44.00M |
| June 30, 2026 | -76.00M |
| March 31, 2026 | 386.00M |
| December 31, 2025 | -65.00M |
| September 30, 2025 | -115.00M |
| June 30, 2025 | -38.00M |
| March 31, 2025 | -172.00M |
| December 31, 2024 | -296.00M |
| September 30, 2024 | -75.00M |
| June 30, 2024 | -46.00M |
| March 31, 2024 | -96.00M |
| December 31, 2023 | -81.00M |
| September 30, 2023 | -55.00M |
| June 30, 2023 | -70.00M |
| Date | Value |
|---|---|
| March 31, 2023 | -54.00M |
| December 31, 2022 | -61.00M |
| September 30, 2022 | -213.00M |
| June 30, 2022 | -83.00M |
| March 31, 2022 | -63.00M |
| December 31, 2021 | -133.00M |
| September 30, 2021 | -61.00M |
| June 30, 2021 | -249.00M |
| March 31, 2021 | -38.00M |
| December 31, 2020 | -127.00M |
| September 30, 2020 | -41.00M |
| June 30, 2020 | -41.00M |
| March 31, 2020 | -49.00M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Viatris, Inc. | 292.30M |
| Pacira Biosciences, Inc. | 60.81M |
| ANI Pharmaceuticals, Inc. | -13.50M |
| Corcept Therapeutics, Inc. | -131.99M |
| Veru, Inc. | 1.802M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 370.00M |
| Cash from Financing (Quarterly) | -5.00M |
| Free Cash Flow | 735.00M |
| Free Cash Flow Per Share (Quarterly) | 1.197 |
| Free Cash Flow to Equity (Quarterly) | 325.00M |
| Free Cash Flow to Firm (Quarterly) | 396.10M |
| Free Cash Flow Yield | 20.13% |